Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments
Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments
- Disease:Chronic inflammatory demyelinating polyradiculoneuropathy
- Substances:Riliprubart
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Riliprubart
- Sponsor:Sanofi-Aventis Recherche & Developpement











